Related Experiment Videos
Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants
C Romagnoli1, M P De Carolis, U Muzii
1Department of Pediatrics, Catholic University of the Sacred Heart, Rome, Italy.
Insights
Caffeine citrate effectively reduced apnea in preterm infants. A lower maintenance dose (2.5 mg/kg) showed fewer side effects like tachycardia and gastrointestinal issues compared to a higher dose.
Area of Science:
- Neonatology
- Pharmacology
- Pediatrics
Background:
- Idiopathic apnea is common in preterm infants.
- Apnea of prematurity can lead to adverse outcomes.
- Caffeine is a standard treatment for apnea of prematurity.
Purpose of the Study:
- To evaluate caffeine citrate for preventing idiopathic apnea in preterm infants.
- To compare the efficacy and safety of two oral maintenance doses of caffeine citrate.
Main Methods:
- Thirty-seven preterm infants (gestation < 32 weeks) were studied.
- Intravenous loading dose: 10 mg/kg caffeine citrate.
- Oral maintenance regimens: 5 mg/kg (Group I) vs. 2.5 mg/kg (Group II).
Main Results:
- Both caffeine citrate groups showed a significant decrease in apneic spells versus controls.
- Group II (2.5 mg/kg) had significantly fewer side effects (tachycardia, GI intolerance) than Group I.
- Group II exhibited lower theophylline plasma levels than Group I.
Conclusions:
- Caffeine citrate is effective in reducing apnea in preterm infants.
- A lower maintenance dose (2.5 mg/kg) offers a better safety profile with comparable efficacy.
- Lower theophylline levels correlate with reduced side effects.
Abstract:
The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated. Thirty-seven preterm infants born before the 32nd week of gestation were studied. After an intravenous loading dose of 10 mg/kg of caffeine citrate, two different oral maintenance regimens were followed: 5 mg/kg in Group I and 2.5 mg/kg in Group II. A significant decrease in the number of apneic spells occurred in both treated groups as compared with a control group. In Group II, the frequency of side effects such as tachycardia and gastrointestinal intolerance was significantly lower than in Group I. Group II theophylline plasma levels were significantly lower than those of Group I. The lower Group II theophylline levels presumably explain the reduced frequency of side effects.